Subject(s)
Azacitidine/analogs & derivatives , Leukemia, Myeloid, Acute/pathology , Membrane Proteins/analysis , Myelodysplastic Syndromes/pathology , Proto-Oncogene Proteins/analysis , Tumor Suppressor Proteins/analysis , Antimetabolites, Antineoplastic/pharmacology , Azacitidine/administration & dosage , Azacitidine/pharmacology , Bone Marrow/chemistry , Case-Control Studies , Cell Line , DNA Methylation , Decitabine , Humans , Leukemia, Myeloid, Acute/mortality , Myelodysplastic Syndromes/mortality , Survival Analysis , Treatment OutcomeABSTRACT
NOD mice are used as experimental models as they develop type 1 diabetes mellitus (DM-1) spontaneously, with a strong similarity to the human disease. Diabetes mellitus type 1 is characterized by the destruction of the islet, orchestrated by T lymphocytes that induce cytokine release like IL-1beta, promoting an inflammatory process. Diacerhein has antiinflammatory properties, inhibiting IL-1. However, the mechanisms involved in immune modulation are not completely understood. In the present study, serum and pancreatic islets were isolated to investigate the relationship between IL-1beta, IFN-gamma, IL-12 and TNF-alpha expression and diabetes onset, morphological aspects, and diacerhein dose dependence in animals treated with different doses (5, 10 and 50 mg/kg/day) and the control group (saline solution). The results demonstrated upregulation of mRNA islets and downregulation of the serum concentration of IL-1beta, IL-12 and TNF-alpha in the group treated with 5 and 10 mg/kg/day diacerhein, when compared with the saline group, and increased IFN-gamma serum concentration in the group treated with 50 mg/kg/day. These results suggest that diacerhein in NOD mice, decreases, in a dose-dependent manner, the diabetes frequency downregulating proinflammatory cytokines, such as IL-1beta, TNF-alpha, IFN-gamma and IL-12 at posttranscriptional or posttranslational level. Furthermore, using the HPLC method, diacerhein and rhein (active metabolite) were detected in serum and pancreas of treated mice.
Subject(s)
Anthraquinones/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cytokines/metabolism , Diabetes Mellitus, Type 1/immunology , Islets of Langerhans/immunology , Animals , Anthraquinones/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cytokines/blood , Diabetes Mellitus, Type 1/metabolism , Interferon-gamma/blood , Interferon-gamma/drug effects , Interferon-gamma/metabolism , Interleukin-1/blood , Interleukin-1/metabolism , Interleukin-12/blood , Interleukin-12/metabolism , Islets of Langerhans/drug effects , Mice , Mice, Inbred NOD , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/drug effects , Tumor Necrosis Factor-alpha/metabolismABSTRACT
NOD (non-obese diabetic) mice develop type 1 diabetes mellitus spontaneously and with a strong similarity to the human disease. Differentiation and function of pancreas beta cells are regulated by a variety of hormones and growth factors, including the nerve growth factor (NGF). Gangliosides have multiple immunomodulatory activities with immunosuppressive properties, decreasing lymphoproliferative responses and modulating cytokine production. In the present study, serum, pancreas islets and spleen mononuclear cells from NOD mice treated with monosialic ganglioside GM1 (100 mg/kg/day) and the group control which received saline solution were isolated to investigate the proinflammatory cytokines (IL-1beta, IFN-gamma, IL-12, TNF-alpha), NGF and its high-affinity receptor TrkA, peri-islet Schwann cells components (GFAP, S100-beta) expression and the relationship with diabetes onset and morphological aspects. Our results suggest that GM1 administration to female NOD mice beginning at the 4th week of life is able to reduce the index of inflammatory infiltrate and consequently the expression of diabetes, modulating the expression of proinflammatory cytokines (IL-12, IFN-gamma, TNF-alpha and IL-1beta). Furthermore, GM1 increases GFAP, S-100beta and NGF in pancreas islets, factors involved in beta cell survival.
Subject(s)
Cytokines/metabolism , Diabetes Mellitus, Type 1/immunology , G(M1) Ganglioside/metabolism , Mice, Inbred NOD , Nerve Growth Factor/metabolism , Receptor, trkA/metabolism , Age of Onset , Animals , Cytokines/genetics , Female , G(M1) Ganglioside/administration & dosage , Glial Fibrillary Acidic Protein , Humans , Islets of Langerhans/cytology , Islets of Langerhans/metabolism , Male , Mice , Nerve Growth Factor/genetics , Nerve Growth Factors/genetics , Nerve Growth Factors/metabolism , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Receptor, trkA/genetics , S100 Calcium Binding Protein beta Subunit , S100 Proteins/genetics , S100 Proteins/metabolism , Schwann Cells/cytology , Schwann Cells/metabolism , Spleen/cytology , Spleen/metabolismABSTRACT
Two variants of this Walker 256 tumor have been previously reported as Walker 256 A and variant AR. The variant A has more aggressive property than variant AR and can induce systemic effects such as anorexia, sodium and water retention, followed by weight loss and death. The mechanisms involved in enhancing tumor regression and progression in this model are still incompletely understood. In the present study, serum and spleen mononuclear cells and tumor cells from animals inoculated with variants A and AR, were isolated to investigate the TGF-beta, IL-12, IFN-gamma and TNF-alpha and relationship with anemia, weight of animals, weight of spleen, volume of tumor and osmotic fragility compared with controls inoculated with Ringer Lactate. Results demonstrate that the group inoculated with variant A, compared to variant AR, shows high levels of TGF-beta gene expression in both tumor tissue and spleen cells, no expression of IFN-gamma and a progressive and higher levels of IL-12 in tumor tissue without inflammatory infiltrate visualized by optical microscopy. These results suggest that the aggressively of variant A is relate to cytokine modulation, facilitating the growth and escape of tumor cells. Furthermore, IL-12 seems to be constitutively expressed in both tumor lineage A and AR.